Beijing Tiantan Hospital Affiliated to Capital Medical University

What Beijing Tiantan Hospital Affiliated to Capital Medical University does

Beijing Tiantan Hospital Affiliated to Capital Medical University (首都医科大学附属北京天坛医院) is a public, government-affiliated Class III Grade A tertiary comprehensive hospital located in Fengtai District, Beijing. Founded in 1956 and administered by the Beijing Municipal Health Commission, it operates 29 clinical departments under Capital Medical University's Fifth Clinical Medical College and holds national-level designations as the National Neurological Disease Clinical Research Center, National Neurological Disease Quality Control Center, and National Medical Center for Neurological Diseases (Beijing). Its core specialty is clinical neuroscience, with neurosurgery and neurology as the institutional lead, supported by a 24-hour emergency department, a dedicated International Department, and a comprehensive inpatient and outpatient operation serving both Beijing residents and national referrals.

The hospital's product and technology portfolio combines direct clinical care with a substantial clinical research apparatus. Beyond standard tertiary services, it runs a Clinical Trial Center/National Clinical Trial Institution Office, an AI Medical Device Clinical Trial Center, a Cerebrovascular Disease Innovation Drug/Device Clinical Research Center, a Data Center, and a Beijing Municipal Neurosurgery Research Institute. It led the multicenter Phase I trial of XellSmart's XS411, an allogeneic iPSC-derived dopaminergic neural progenitor cell therapy for Parkinson's disease, and coordinated the Golden Bridge II trial of an AI-assisted clinical decision support system across 77 hospitals with 21,600+ acute ischemic stroke patients (2021-2023), demonstrating a 25% relative reduction in new vascular events versus usual care.

Commercially, the hospital operates a public-hospital revenue model: medical services are delivered directly to patients through outpatient clinics, inpatient wards, and emergency and international channels, with revenue flowing primarily through China's public health insurance system under DRG/DIP-style reimbursement, supplemented by patient out-of-pocket payments, VIP/specialty clinic fees, and clinical trial/research grants. Leadership is headed by Party Committee Deputy Secretary and President Wang Yongjun, an Academician of the Chinese Academy of Sciences, alongside a Party Secretary Yue Xiaolin and standing committee executives. As a state medical institution, the hospital has no private equity, venture capital, or minority shareholders and is not listed on any exchange.

Name

Beijing Tiantan Hospital Affiliated to Capital Medical University

Legal name

首都医科大学附属北京天坛医院

Website

https://bjtth.org

Company type

Private

Founded year

1956

Operating status

Operating

Headcount range

1–10 employees

Short description

Beijing Tiantan Hospital is a public Class III Grade A tertiary hospital in Beijing, affiliated with Capital Medical University, specializing in neurology and neurosurgery, and designated as China's National Clinical Research Center, Quality Control Center, and Medical Center for Neurological Diseases.

Ownership category

akta.pro rank

Product category

Tertiary Neurological Healthcare Services

NAICS

General Medical and Surgical Hospitals (622110)

SIC

Services-General Medical & Surgical Hospitals, Nec (8062)

akta.pro primary industry

Neurology & Neurosurgical Specialty Hospitals (HLAFAHAD)

Keywords

• Tertiary hospital services
• Neurological disease treatment
• Neurosurgery services
• Clinical research services
• Emergency medical care

Headquarters

HQ city

Fengtai

HQ country

China

HQ region

Asia

Offices1 record

Markets served

GTM type

B2C

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Infrastructure

Revenue model

1. Medical Services Revenue: Revenue generated from providing medical services to patients including consultations, treatments, surgeries, and hospital stays covered by health insurance or patient payments

Go-to-market motion1 record

Distribution channels3 records

Marketing channels4 records

Core offering

Beijing Tiantan Hospital is a Class A tertiary comprehensive hospital that delivers inpatient and outpatient medical care, surgery, emergency services, and clinical research across 29 clinical departments, with neurosurgery and neurology as its leading specialties. The hospital also serves as the National Clinical Research Center for Neurological Diseases, conducting clinical trials including AI-assisted clinical decision support systems for stroke care and cell therapy research for Parkinson's disease.

Product overview

Beijing Tiantan Hospital is a Class A tertiary comprehensive hospital that serves as a national神经系统疾病临床医学研究中心 (National Clinical Research Center for Neurological Diseases) and 国家神经疾病医学中心 (National Medical Center for Neurological Diseases). The hospital offers comprehensive medical services through 29 clinical departments, with neurosurgery and neurology as its leading specialties. The institution conducts clinical trials and research including AI-assisted clinical decision support systems for stroke care, cell therapies for Parkinson's disease, and various neurological disease interventions. The product portfolio includes specialized research centers (National Clinical Trial Institution, AI Medical Device Clinical Trial Center, Cerebrovascular Disease Innovation Medical Device Research Center) alongside core clinical care services.

Differentiator

Problem solved

Functional benefit

Products and services

• Medical Services (Neurosurgery, Neurology, and General Medicine) Comprehensive tertiary medical services including neurosurgery center, neurology center, surgery, internal medicine, cardiology, oncology, and other clinical departments providing diagnosis, treatment, surgery, and rehabilitation to patients with neurological and general medical conditions.
• Emergency Medical Services 24-hour emergency department providing acute medical care for critical neurological, cardiovascular, and general medical emergencies, including stroke, brain hemorrhage, brain infarction, and brain trauma.
• International Patient Services

Quantifiable outcome

• 25% reduction in vascular events at 3 months with AI-assisted clinical decision support system
• +1 more outcomes

Named customers1 record

Segments1 record

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability3 records

Feature2 records

Partnerships

Three partnerships are on record, tiered core.

• Peking Union Medical College HospitalcoreStrategic or Co-development Partner · 1 April 2026Collaborated in Phase I clinical trial for XS411 Parkinson's disease cell therapy, contributing to the multicenter research alongside Beijing Tiantan Hospital as the lead site
• Second Affiliated Hospital of Soochow UniversitycoreStrategic or Co-development Partner · 1 April 2026Collaborated in Phase I clinical trial for XS411 Parkinson's disease cell therapy, contributing as one of the clinical trial sites
• 77 Hospitals Across ChinacoreStrategic or Co-development Partner · 1 January 2021Golden Bridge II clinical trial conducted across 77 hospitals in China with over 21,600 adults with acute ischemic stroke between 2021 and 2023, testing AI-assisted clinical decision support system

Scale indicators5 records

Recent moves6 records

Expansion highlights4 records

Direct peers

• The First Affiliated Hospital of Zhejiang University: A top-ranked Chinese tertiary academic hospital known for clinical research infrastructure and neurology/neurosurgery capabilities; comparable to Tiantan as a national-level research hospital and clinical trial site.
• Huashan Hospital Affiliated to Fudan University: A leading Chinese Class A tertiary comprehensive hospital with a nationally renowned neurosurgery and neurology department, directly comparable to Tiantan as a top-tier Chinese academic neurology center competing for clinical trials, talent, and complex referrals.
• Peking Union Medical College Hospital: China's premier Class A tertiary academic hospital and a direct peer in elite neurology/neurosurgery care and clinical research; has co-led the XS411 Parkinson's Phase I trial with Tiantan and shares the same referral-tier patient pool in Beijing.
• Xuanwu Hospital Capital Medical University: A sister Capital Medical University-affiliated tertiary hospital in Beijing with a strong neurology and neurosurgery program; competes head-to-head with Tiantan for Beijing neurology patients, talent, and sponsored trials.
• West China Hospital of Sichuan University: One of China's largest Class A tertiary academic hospitals with comprehensive neurosciences programs; comparable to Tiantan in scale, breadth of clinical departments, and participation in national multicenter neurological trials.
• Tongji Hospital Affiliated to Tongji Medical College of HUST: A major Chinese tertiary academic hospital with strong neurology and neurosurgery capabilities; comparable as a peer academic medical center participating in nationwide stroke and neurological research networks.
• Xiangya Hospital Central South University: A leading Chinese tertiary academic medical center with established neurosciences programs; directly comparable in tier, scope of services, and participation in national neurological clinical trials.

Broad incumbents

• Mayo Clinic: A globally leading integrated academic medical center with premier neurology and neurosurgery departments and advanced clinical research capabilities; a broader incumbent benchmark for Tiantan's aspiration to international neurology leadership.
• Massachusetts General Hospital: A Harvard-affiliated global leader in neurology and neuroscience research with extensive clinical trial activity; comparable to Tiantan as a benchmark for translational neuroscience, AI in neurology, and cell therapy research.
• Johns Hopkins Hospital: A leading global academic medical center with top-ranked neurology, neurosurgery, and stroke programs; relevant as an international benchmark for the scale and depth of clinical neuroscience research Tiantan is pursuing.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat6 records

Key risks4 records

Key highlights6 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles12 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Beijing Tiantan Hospital Affiliated to Capital Medical University